Oxford Immune Algorithmics
- Industry
- Healthcare Technology
- Founded Year
- 2018
- Headquarters
- Reading, Berkshire, United Kingdom
- Employee Count
- 33
Key People
- Hector Zenil - Founder and Chief Visionary Officer
- Jrgen Riedel - Co-founder and Chief Technology Officer
- Lionel Khalil - Chief Financial Officer
- Kourosh Saeb-Parsy - Chief Medical Officer
- Pamela Winsor - Chairwoman of the Board
- Allan Bezanson - Director
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with backgrounds in AI, computer science, and medicine.
The founders and key executives have extensive experience in relevant fields, enhancing the company's capability to develop and implement advanced healthcare solutions.
- Clinical Need
-
Aspect: Very Strong
Summary: The demand for remote health monitoring and precision medicine is increasing, especially post-pandemic.
The COVID-19 pandemic has accelerated the adoption of remote healthcare solutions, creating a significant market opportunity for technologies like Algocyte.
- Competition
-
Aspect: Somewhat crowded
Summary: The market for remote health monitoring has several players, but OIA's AI-driven approach offers differentiation.
The healthcare technology sector is competitive; however, OIA's integration of AI for personalized health monitoring sets it apart from many competitors.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing AI-driven health monitoring systems involves complex data analysis but is achievable with current technology.
Implementing AI in healthcare requires handling sensitive data and ensuring accuracy, but advancements in technology and expertise make this feasible.
- Patent
-
Aspect: Strong
Summary: Algocyte is patent-protected, providing a competitive advantage.
Having a patent for Algocyte secures intellectual property rights, potentially deterring competitors and attracting investors.
- Financing
-
Aspect: Well-funded
Summary: OIA has secured significant funding from reputable investors, indicating strong financial backing.
The 5.1 million funding round led by Medtech AI Ltd and participation from investors like SFC Capital provides the necessary capital for R&D and market expansion.
- Regulatory
-
Aspect: Running FIH
Summary: OIA is deploying Algocyte devices for testing and validation with leading NHS hospitals.
Collaborations with NHS institutions for testing and validation suggest that OIA is actively working towards meeting regulatory requirements for their products.
Opportunity Rollup
- Odds of Success
- 3.7
- Peak Market Share
- 4.5
- Segment CAGR
- 10.7%
- Market Segment
- Remote Health Monitoring
- Market Sub Segment
- AI-driven Personalized Medicine
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.22 |
| 2 | 0.68 |
| 3 | 1.58 |
| 4 | 3.15 |
| 5 | 4.50 |
Key Takeaway
Oxford Immune Algorithmics is well-positioned in the growing remote health monitoring market, leveraging AI to offer personalized healthcare solutions, supported by a strong team and substantial funding.